Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 49   

Articles published

AEGR 30.07 +0.07 (0.23%)
price chart
Aegerion Pharmaceuticals (AEGR) Scheduled to Post Earnings on Tuesday
The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $33.58 million. On average, analysts expect Aegerion Pharmaceuticals to post $-0.94 EPS for the current fiscal year and $2.16 EPS for the next fiscal year.
Related articles »  
Aegerion Pharmaceuticals, Inc. (AEGR): New Analyst Report from Zacks Equity ...
Aegerion reported a loss of $0.54 per share in the first quarter, wider than the Zacks Consensus Estimate for a loss of $0.35 but narrower than the year-ago loss of $0.64.
Aegerion Pharmaceuticals Given Neutral Rating at Zacks (AEGR)  Mideast Time
Healthcare New Lows: Aegerion Pharmaceuticals (NASDAQ:AEGR ...  Crazy Joys
Related articles »  
Review on Biotech Stocks -- Incyte, ACADIA Pharma, Cel-Sci, Aegerion Pharma ...
Ltd (NASDAQ: INCY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Cel-Sci Corporation (NYSE MKT: CVM), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and ImmunoGen Inc. (NASDAQ: IMGN). Free research on these five companies can be ...
Aegerion Pharmaceuticals Stock Rating Reaffirmed by Zacks (AEGR)  Intercooler
Related articles »  
Recent Happenings In Biotech Industry: Celgene Corporation (CELG), Aegerion ...
... stock to $292 from $99 and kept a Buy rating on the stock. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Amicus Therapeutics, Inc. (NASDAQ:FOLD) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) were climbing higher seemingly in sympathy with BIIB.
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on July 1, 2014, Aegerion granted ...
Related articles »  
Stocks Landing in the Bearish Zone- Aegerion Pharmaceuticals, Inc. (NASDAQ ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) ended its recent business day with the loss of -1.82% and closed at the price of $26.93 after opening at $27.35.
Biotech New Lows: Aegerion Pharmaceuticals (NASDAQ:AEGR), Kite Pharma ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) reported a loss of $0.54 per share in the first quarter, wider than the Zacks Consensus Estimate for a loss of $0.35 but narrower than the year-ago loss of $0.64.
Related articles »  
Big Movers � NQ Mobile Inc (ADR) (NYSE:NQ), Aegerion Pharmaceuticals ...
On 25 JUNE Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.35) by $0.10.
Healthcare New Lows: Aegerion Pharmaceuticals (NASDAQ:AEGR), Volcano ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that on July 1, 2014, Aegerion granted stock ...
Related articles »  
NASDAQ Stocks Touched new lows: Aegerion Pharmaceuticals, Inc. (NASDAQ ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced that on July 1, 2014, Aegerion granted stock options to purchase an aggregate of 40,500 shares of common stock to nine new employees under the inducement stock option program described ...
Related articles »